Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $38 | In Stock | |
2 mg | $52 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $133 | In Stock | |
25 mg | $261 | In Stock | |
50 mg | $397 | In Stock | |
100 mg | $590 | In Stock | |
500 mg | $1,260 | In Stock | |
1 mL x 10 mM (in DMSO) | $90 | In Stock |
Description | Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. |
Targets&IC50 | SGLT2:1.8 nM, SGLT1:36 nM |
In vitro | LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM for mouse SGLT1 and 0.6 nM for mouse SGLT2, respectively. [2] |
In vivo | In mice, LX4211 (60 mg/kg, p.o.) reduces intestinal glucose absorption by inhibiting SGLT1, resulting in net increases in GLP-1 and PYY release and decreases in GIP release and blood glucose excursions. [2] In nonobese diabetes-prone mice with type 1 diabetes, Sotagliflozin (30 mg/kg) significantly improves glycemic control, without increasing the rate of hypoglycemia measurements. [3] |
Alias | LX-4211, LP-802034 |
Molecular Weight | 424.94 |
Formula | C21H25ClO5S |
Cas No. | 1018899-04-1 |
Smiles | CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1 |
Relative Density. | 1.37 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (117.66 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 14 mg/mL (32.9 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.